Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

DISEASE CHARACTERISTICS:

• Undergoing autologous peripheral blood stem cell transplantation and stem cell mobilization using cyclophosphamide

• Candidate (per institutional requirements) for autologous peripheral blood stem cell transplantation

  • No psychiatric illness or multi-system organ failure
• No nausea at baseline

PATIENT CHARACTERISTICS:

• SWOG performance status 0-2
• Fewer than 5 alcoholic drinks per day within the past year
• No current illness requiring chronic systemic steroids or requirement for chronic use of anti-emetics
• No gastrointestinal obstruction or active peptic ulcer disease
• AST and ALT ≤ 3 times upper limit of normal (ULN)
• Bilirubin ≤ 3 times ULN
• Alkaline phosphatase ≤ 3 times ULN
• Creatinine ≤ 2 mg/dL
• No known hypersensitivity to any component of the study regimen
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception
• No unrelenting hiccups

PRIOR CONCURRENT THERAPY:

• No chronic therapeutic warfarin > 1 mg dose per day
• No other concurrent investigational agents
• No concurrent oral contraceptives (except for stopping menses), tolbutamide, phenytoin, midazolam, ketoconazole, rifampin, paroxetine hydrochloride, or diltiazem hydrochloride
• No concurrent illegal drugs